Skip to main content
. Author manuscript; available in PMC: 2015 Nov 2.
Published in final edited form as: Clin Immunol. 2014 Aug 19;155(1):60–70. doi: 10.1016/j.clim.2014.08.004

Figure 1.

Figure 1

IgG anti-citrullinated HSP90 antibody levels in BALF versus serum. A) Bar graphs depict relative ELISA-determined IgG anti-citrullinated HSP90α antibody levels (expressed as OD450 units standardized by comparison to serial dilutions of a RA-ILD positive control serum) for BALF (1:4 dilution) and corresponding serum samples (1:500 dilution) derived from patients with RA-ILD (16, 126, 138), RA-subclinical ILD (113 (BALF only), 162), and RA-no ILD (170, 191). B) Bar graphs illustrate relative IgG anti-citrullinated HSP90β antibody levels in BALF (1:4 dilution) and serum samples (1:500 dilution) obtained from the same profile of RA patients, using citHSP90β (1 µg/ml) as substrate antigen for ELISA. Standardized OD450 values were again calculated based on comparison to OD450 readings generated by serial dilutions of a known reference serum. C) In this panel, individual plots demonstrate relative IgG antibody responses against citrullinated (1C–5C, 6C–10C) versus uncitrullinated [1–10] peptide pools derived from HSP90 sequences. While blue curves correspond to BALF samples (1:2 dilution) from designated RA patients with different ILD phenotypes, red curves represent matching serum samples (1:250 dilution) from the same individual. Standardized OD450 units were adjusted based on the ratio of OD450 sample:OD450 reference serum. Error bars represent SEM in all panels.